Real-world challenges for hepatitis C virus medications: a critical overview

References

• Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, et al. 2014. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 370:1483–1493.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, et al. 2014. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 370:1889–1898.
   PubMed Web of Science ®Google Scholar
• Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, et al. 2015. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 16:1344–1354.
   PubMed Web of Science ®Google Scholar
• AASLD/IDSA HCV Guidance Panel 2015. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62:932–954. Available from: http://www.onlinelibrary.wiley.com/doi/10.1002/hep.27950/full.html.
   PubMed Web of Science ®Google Scholar
• Asma A, Daniel F. 2015. Mechanisms of hepatitis C viral resistance to direct acting antivirals. Viruses. 7:6716–6729.
   PubMed Web of Science ®Google Scholar
• Asselah T, Hézode C, Qaqish BR, ElKhashab M, Hassanein T, Papatheodoridis G, Feld JJ, Moreno C, Zeuzem S, Ferenci P, et al. 2016. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. Lancet. 1:25–35.
   PubMedGoogle Scholar
• Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, Mullhaupt B, Horsmans Y, Weiland O, Reesink HW, et al. 2014. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 147:359–365. e351.
   PubMed Web of Science ®Google Scholar
• Aronsohn A, Jensen D. 2014. Expanding access to hepatitis C virus care: a call to deconstruct individualized therapy. Hepatology. 59:13–15.
   PubMed Web of Science ®Google Scholar
• Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. 2015. Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 163:215–223.
   PubMed Web of Science ®Google Scholar
• Bartenschlager R, Lohmann V. 2000. Replication of hepatitis C virus. J Gen Virol. 81:1631–1648.
   PubMed Web of Science ®Google Scholar
• Bartenschlager R, Frese M, Pietschmann T. 2004. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res. 63:71–180.
   PubMed Web of Science ®Google Scholar
• Bressanelli S, Tomei L, Rey FA, De Francesco R. 2002. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J Virol. 76:3482–3492.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. 2016. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 3:3–14.
   PubMed Web of Science ®Google Scholar
• Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB. 2013. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration. Clin Gastroenterol Hepatol. 11:1503–1510.
   PubMed Web of Science ®Google Scholar
• Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R. 2013. Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med. 15158:114–123.
   PubMed Web of Science ®Google Scholar
• Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, et al. 2016 . Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 65:727–733.
   PubMed Web of Science ®Google Scholar
• Craxi A, Laffi G, Zignego AL. 2008. Hepatitis C virus (HCV) infection: a systemic disease. Mol Aspects Med. 29:85–95.
   PubMed Web of Science ®Google Scholar
• Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, et al. 2015. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 373:2618–2628.
   PubMed Web of Science ®Google Scholar
• Domingo E, Holland J. 1988. High error rates, population equilibrium, and evolution of RNA replication systems. In: Domingo E, Holland JJ, editors. RNA genetics. Boca Raton, Florida: CRC Press; p. 3–36.
   Google Scholar
• Domingo E, Holland J. 1994. Mutation rates and rapid evolution of RNA viruses. In: Morse SS, editor. Evolutionary biology of viruses. New York: Raven Press; p. 161–184.
   Google Scholar
• Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Muhlberger N, Siebert U, Moreno C, Hatzakis A, Rosenberg W, et al. 2012. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology. 143:974–985 e914.
   PubMed Web of Science ®Google Scholar
• Deuffic-Burban S, Schwarzinger M, Obach D, Mallet V, Pol S, Pageaux GP, Canva V, Deltenre P, Roudot-Thoraval F, Larrey D, et al. 2014. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). J Hepatol. 61:7–14.
   PubMed Web of Science ®Google Scholar
• Dore G, Altice F, Litwin AH, Dalgard O, Gane E, Shibolet O, Leutkemeyer A, Nahass R ,Peng CY, Conway B, et al. 2015. C-EDGE CO-STAR: efficacy of grazoprevir and elbasvir in persons who inject drugs (PWID) receiving opioid agonist therapy. Presented at: 2015 Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco; Abstract 40.
   Google Scholar
• Elbasvir-Grazoprevir (Zepatier) clinical trials [Internet]. Hepatitis C Online, University of Washington. [cited 2016 Oct 25]. Available from: http://www.hepatitisc.uw.edu/page/treatment/drugs/elbasvir-grazoprevir#drug-summary.html.
   Google Scholar
• Federica B, Fabio C, Pietro A, Cristina C, Giuseppe FF, Marco L, Giuseppe M, Gabriella V. 2016. Development of Hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. Presented at: 51st Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain. Abstract LBP506.
   Google Scholar
• Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, et al. 2014. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 370:1983–1992.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, et al. 2015. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 373:2599–2607.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Jacobson IM, Jensen DM, Foster GR, Pol S, Tam E, Jablkowski M, Berak H, Vierling JM, Yoshida EM, et al. 2014. Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 62:294–302.
   PubMed Web of Science ®Google Scholar
• Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, et al. 2015. Sofosbuvir and velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 373:2608–2617.
   PubMed Web of Science ®Google Scholar
• Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, Marinos G, Kaldor JM. 2001. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology. 34:809–816.
   PubMed Web of Science ®Google Scholar
• Freeman J, Sallie R, Kennedy A, Hieu PTN, Freeman J, Jeffreys G, Hill AM. 2016. High sustained virologic response rates using generic direct acting antiviral treatment for hepatitis C, imported into Australia. J Hepatol. 64:S209.
   Google Scholar
• Gale M Jr, Foy EM. 2005. Evasion of intracellular host defence by hepatitis C virus. Nature. 436:939–945.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Subramanian GM, Symonds WT, McHutchison JG, Pang PS. 2014. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 146:736–743 e731.
   PubMed Web of Science ®Google Scholar
• Gao B, Hong F, Radaeva S. 2004. Host factors and failure of interferon-alpha treatment in hepatitis C virus. Hepatology. 39:880–890.
   PubMed Web of Science ®Google Scholar
• Gellad ZF, Reed SD, Muir AJ. 2012. Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C. Antivir Ther (Lond). 17:1189–1199.
   PubMed Web of Science ®Google Scholar
• Grebely J, Dore GJ. 2014. Can hepatitis C virus infection be eradicated in people who inject drugs?. Antiviral Res. 104:62–72.
   PubMed Web of Science ®Google Scholar
• Gutierrez JA, Lawitz EJ, Poordad F. 2015. Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. J Viral Hepat. 22:861–870.
   PubMed Web of Science ®Google Scholar
• Han B, Dvory-Sobol H, Greenstein A, McCarville JF, Hung M, Liu X, Miller MD, Mo H, et al. 2015. Development and application of a fast, reproducible assay to measure HCV NS3 protease activity using Escherichia coli lysate. J Virol Methods. 225:76–86.
   PubMed Web of Science ®Google Scholar
• Harris RJ, Thomas B, Griffiths J, Costella A, Chapman R, Ramsay M, De Angelis D, Harris HE. 2014. Increased uptake and new therapies are needed to avert rising hepatitis C-related end stage liver disease in England: modelling the predicted impact of treatment under different scenarios. J Hepatol. 61:530–537.
   PubMed Web of Science ®Google Scholar
• Hellard M, Doyle JS, Sacks-Davis R, Thompson AJ, McBryde E. 2014. Eradication of hepatitis C infection: the importance of targeting people who inject drugs. Hepatology. 59:366–369.
   PubMed Web of Science ®Google Scholar
• Hsu YH, Muo CH, Liu CY, Tsai WC, Hsu CC, Sung FC, Kao CH. 2015. Hepatitis C virus infection increases the risk of developing peripheral arterial disease: a 9-year population-based cohort study. J Hepatol. 62:519–525.
   PubMed Web of Science ®Google Scholar
• Hezode C, Alric L, Brown A, Hassanein T, Rizzetto M, Buti M, Bourliere M, Thabut D, Molina E, Rustgi V, et al. 2015. Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4). Antivir Ther. 21:195–205.
   PubMed Web of Science ®Google Scholar
• Hezode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, et al. 2015. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut. 64:948–956.
   PubMed Web of Science ®Google Scholar
• Hezode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, Marcellin P, Hall C, Schnell G, Pilot-Matias T, et al. 2015. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 385:2502–2509.
   PubMed Web of Science ®Google Scholar
• Hill A, Khoo S, Fortunak J, Simmons B, Ford N. 2014. Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis. 58:928–936.
   PubMed Web of Science ®Google Scholar
• Innes H, Goldberg D, Dillon J, Hutchinson SJ. 2015. Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?. Gut. 64:1800–1809.
   PubMed Web of Science ®Google Scholar
• Innes H, Goldberg D, Dusheiko G, Hayes P, Mills PR, Dillon JF, Aspinall E, Barclay ST, Hutchinson SJ. 2014. Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model. J Hepatol. 60:1118–1126.
   PubMedGoogle Scholar
• Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Delahooke TE, Dillon JF, Forrest E, Fraser A, Gillespie R, et al. 2011. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology. 54:1547–1558.
   PubMedGoogle Scholar
• Innes HA, Hutchinson SJ, Barclay S, Cadzow E, Dillon JF, Fraser A, Goldberg DJ, Mills PR, McDonald SA, Morris J, et al. 2013. Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness. Hepatology. 57:451–460.
   PubMed Web of Science ®Google Scholar
• Innes HA, McDonald SA, Dillon JF, Allen S, Hayes PC, Goldberg D, Mills PR, Barclay ST, Wilks D, Valerio H, et al. 2015. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology. 62:355–364.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, et al. 2013. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 368:1867–1877.
   PubMed Web of Science ®Google Scholar
• Jayasekera CR, Barry M, Roberts LR, Nguyen MH. 2014. Treating hepatitis C in lower-income countries. N Engl J Med. 370:1869–1871.
   PubMed Web of Science ®Google Scholar
• Kim JL, Morgenstern KA, Griffith JP, Dwyer MD, Thomson JA, Murcko MA, Lin C, Caron PR, et al. 1998. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure. 6:89–100.
   PubMed Web of Science ®Google Scholar
• Koch U, Narjes F. 2007. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Curr Top Med Chem. 7:1302–1329.
   PubMed Web of Science ®Google Scholar
• Kwo P, Gane E, Peng CY, et al. 2015. Efficacy and safety of grazoprevir/elbasvir+/− RBV for 12 or 16 weeks in patients with HCV G1, G4, or G6 infection who previously failed peginterferon/RBV: C-EDGE treatment experienced. Presented at: 50th Annual meeting of the European Association for the Study of the Liver, Vienna, Austria. Abstract P0886.
   Google Scholar
• Kabiri M, Jazwinski AB, Roberts MS, Schaefer AJ, Chhatwal J. 2014. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med. 161:170–180.
   PubMed Web of Science ®Google Scholar
• Kandeel AM, Talaat M, Afifi SA, El-Sayed NM, Abdel Fadeel MA, Hajjeh RA, Mahoney FJ. 2012. Case control study to identify risk factors for acute hepatitis C virus infection in Egypt. BMC Infect Dis. 12:294
   PubMed Web of Science ®Google Scholar
• Kohli A, Kattakuzhy S, Sidharthan S, Nelson A, McLaughlin M, Seamon C, Wilson E, Meissner EG, Sims Z, Silk R, et al. 2015. Four-week direct-acting antiviral regimens in noncirrhotic patients with hepatitis C virus genotype 1 infection: an open-label, nonrandomized trial. Ann Intern Med. 163:899–907.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, et al. 2013. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 381:2100–2107.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, et al. 2014. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 370:1879–1888.
   PubMed Web of Science ®Google Scholar
• Kwo P, Gitlin N, Nahass R, Bernstein D, Etzkorn K, Rojter S, Schiff E, Davis M, Ruane P, Younes Z, et al. 2016. Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology. 64:370–380.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R, Godofsky E, Herring RW, Poleynard G, Sheikh A, et al. 2016. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology. 64:360–369.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, et al. 2014. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 384:1756–1765.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. 2014. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 383:515–523.
   PubMed Web of Science ®Google Scholar
• Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, Pol S, Stuart K, Tse E, McPhee F, et al. 2016. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology. 63:1430–1441.
   PubMed Web of Science ®Google Scholar
• Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. 1999. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol. 6:937–943.
   PubMedGoogle Scholar
• Lin C, Rice CM. 1995. The hepatitis C virus NS3 serine proteinase and NS4A cofactor: establishment of a cell-free trans-processing assay. Proc Natl Acad Sci USA. 92:7622–7626.
   PubMed Web of Science ®Google Scholar
• Lo Re V, 3rd, Gowda C, Urick PN, Halladay JT, Binkley A, Carbonari DM, Battista K, Peleckis C, Gilmore J, Roy JA, et al. 2016 . Disparities in absolute denial of modern hepatitis C therapy by type of insurance. Clin Gastroenterol Hepatol. 14:1035–1043.
   PubMed Web of Science ®Google Scholar
• Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, Calleja JL, Peck-Radosavljevic M, Mullhaupt B, et al. 2016 . Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 16:685–697.
   PubMed Web of Science ®Google Scholar
• Martell M, Esteban J, Quer J, Genesca J, Weiner A, Esteban R, Guardia J, Gomez J. 1992. Hepatitis C virus (HCV) circulates as appulation of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol. 66:3225–3229.
   PubMed Web of Science ®Google Scholar
• McDonald SA, Innes HA, Hayes PC, Dillon JF, Mills PR, Goldberg DJ, Barclay S, Allen S, Fox R, Fraser A, et al. 2015. What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C? J Hepatol. 62:262–268.
   PubMed Web of Science ®Google Scholar
• Medicaid Denial for Hep C Drugs Nearing 50% in Some States [Internet]. Medscape Gastroenterology, CME & Education, USA. [cited 2017 Feb 13]. Available from: http://www.medscape.com/viewarticle/854708.html
   Google Scholar
• Naggie S, Cooper C, Saag M, Workowski K, Ruane P, Towner WJ, Marks K, Luetkemeyer A, Baden RP, Sax PE, et al. 2015. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 373:705–713.
   PubMed Web of Science ®Google Scholar
• Nault JC, Colombo M. 2016. hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. J Hepatol. 65:663–665.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, et al. 2015. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 61:1127–1135.
   PubMed Web of Science ®Google Scholar
• Palmateer N, Hutchinson S, McAllister G, Munro A, Cameron S, Goldberg D, Taylor A. 2014. Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data. J Viral Hepat. 21:25–32.
   PubMed Web of Science ®Google Scholar
• Perry CM. 2012. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C. Drugs. 72:619–641.
   PubMed Web of Science ®Google Scholar
• Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, Hughes EA, Noviello S, Swenson ES. 2016. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 63:1493–1505.
   PubMed Web of Science ®Google Scholar
• Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, et al. 2014. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 370:1973–1982.
   PubMed Web of Science ®Google Scholar
• Prevost TC, Presanis AM, Taylor A, Goldberg DJ, Hutchinson SJ, De Angelis D. 2015. Estimating the number of people with hepatitis C virus who have ever injected drugs and have yet to be diagnosed: an evidence synthesis approach for Scotland. Addiction. 110:1287–1300.
   PubMed Web of Science ®Google Scholar
• Rajani AK, Ravindra BK, Dkhar SA. 2013. Telaprevir: changing the standard of care of chronic hepatitis C. J Postgrad Med. 59:42–47.
   PubMed Web of Science ®Google Scholar
• Reau NS, Jensen DM. 2014. Sticker shock and the price of new therapies for hepatitis C: is it worth it?. Hepatology. 59:1246–1249.
   PubMed Web of Science ®Google Scholar
• Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S, Diaz A, Vilana R, Darnell A, Varela M, et al. 2016. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol. 65:719–726.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS, Zamor PJ, Orkin C, et al. 2015. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2:e319–e327.
   PubMed Web of Science ®Google Scholar
• Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, Monsour H, Jr., Martin P, Pol S, Londono MC, Hassanein T, et al. 2015. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 386:1537–1545. Oct 17
   PubMed Web of Science ®Google Scholar
• Sarah K, et al. 2016. A novel task shifting model to expand the HCV care continuum: The ASCEND investigation. Presented at: 51st Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain. Abstract LBP524.
   Google Scholar
• Shahid I, WH AL, Hafeez MH, Hassan S. 2014. Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies. Crit Rev Microbiol. 42:535–547.
   PubMed Web of Science ®Google Scholar
• Sibley A, Han KH, Abourached A, Lesmana LA, Makara M, Jafri W, Salupere R, Assiri AM, Goldis A, Abaalkhail F, et al. 2015. The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3. J Viral Hepat. 22:21–41.
   PubMed Web of Science ®Google Scholar
• Simmonds P. 2013. The origin of hepatitis C virus. Curr Top Microbiol Immunol. 369:1–15.
   PubMed Web of Science ®Google Scholar
• Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. 2014. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 59:318–327.
   PubMed Web of Science ®Google Scholar
• Sofosbuvir-Velpatasvir (Epclusa) clinical trials [Internet]. Hepatitis C Online- University of Washington. [cited 2016 Oct 30]. Available from: http://www.hepatitisc.uw.edu/page/treatment/drugs/sofosbuvir-velpatasvir#drug-summary.html.
   Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, et al. 2014. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 370:211–221.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, Slim J, Bhatti L, Gathe J, Ruane PJ, et al. 2015. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 313:1223–1231.
   PubMed Web of Science ®Google Scholar
• Talaat M, Kandeel A, Rasslan O, Hajjeh R, Hallaj Z, El-Sayed N, Mahoney FJ. 2006. Evolution of infection control in Egypt: achievements and challenges. Am J Infect Control. 34:193–200.
   PubMed Web of Science ®Google Scholar
• Talaat N, Yapali S, Fontana RJ, Conjeevaram HS, Lok AS. 2014. Changes in characteristics of hepatitis C patients seen in a liver centre in the United States during the last decade. J Viral Hepat. 22:481–488.
   PubMedGoogle Scholar
• Vignuzzi M, Stone K, Arnold J, Cameron E, Andino R. 2006. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature. 439:344–348.
   PubMed Web of Science ®Google Scholar
• Waked I, Shiha G, Qaqish BR, Esmat G, Yosry A, Hassany M, Soliman R, Mohey AM, Allam N, Zayed N, et al. 2016. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Lancet. 1:36–44.
   PubMedGoogle Scholar
• Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Ormeci N, Van Vlierberghe H, Gschwantler M, Akarca U, et al. 2014. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 21:60–89.
   PubMed Web of Science ®Google Scholar
• What are the redemption trials [Internet]. FixHepC, Hobart, Tasmania, Australia. [cited 2016 Nov 6]. Available from: http://fixhepc.com/forum/redemption/203-so-what-are-the-redemption-trials.html.
   Google Scholar
• Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, Sherman KE, Dretler R, Fishbein D, Gathe JC, Jr, et al. 2015. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 373:714–725. Aug 20
   PubMed Web of Science ®Google Scholar
• Wyles D, Brau N, Kottilil S, et al. 2016. Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase 3 ASTRAL-5 study. Presented at: 51st Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain. Abstract PS104.
   Google Scholar
• Yazdanpanah Y, Schwarzinger M. 2016. Generic antiretroviral drugs and HIV care: an economic review. Med Mal Infect. 46:67–71.
   PubMed Web of Science ®Google Scholar
• Zeremski M, Zibbell JE, Martinez AD, Kritz S, Smith BD, Talal AH. 2013. Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care. WJG.Gastroenterol. 19:7846–7851.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, et al. 2014. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 370:1604–1614.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, et al. 2015. Grazoprevir–Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection. Ann Intern Med. 163:1–13.
   PubMed Web of Science ®Google Scholar